Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 Nef is a multifunctional accessory protein that is essential for the high-titer replication of the human immunodeficiency virus and the progression to AIDS [1, 4]. Lacking enzymatic activity, Nef functions as a molecular adaptor that hijacks host cell signaling and trafficking machinery through various protein-protein interactions [1, 6]. A key interaction involves the binding of the conserved PxxPxR motif in Nef to the Src homology 3 (SH3) domains of host Src-family kinases (SFKs), such as Hck, Lyn, and c-Src [3, 9]. This interaction displaces the SH3 domain from its auto-inhibitory position, leading to the constitutive activation of the kinase [7, 8]. This signaling event is critical for enhancing viral infectivity and promoting immune evasion by facilitating the downregulation of major histocompatibility complex class I (MHC-I) from the surface of infected cells [6, 11, 15]. Small-molecule inhibitors targeting the Nef-SH3 interface are being developed to disrupt these processes, thereby suppressing viral replication and restoring the immune system's ability to recognize and eliminate HIV-infected cells [10, 11, 14]. These inhibitors offer a novel therapeutic approach that could complement existing antiretroviral therapies by targeting viral persistence and immune escape mechanisms [6, 11]. Preclinical studies have identified several chemical scaffolds, including hydroxypyrazoles and isothiazolones, that effectively block this interaction and its downstream effects [10, 11]. The development of these agents faces challenges such as ensuring specificity to avoid interfering with normal host kinase functions and addressing the high mutation rate of the HIV-1 genome [2, 6]. Overall, the Nef-SH3 interface represents a high-value target for the next generation of HIV treatments aimed at achieving a functional cure [1, 14].
Inhibition of the protein-protein interaction between HIV-1 Nef and host Src-family kinase SH3 domains, preventing allosteric kinase activation and restoring MHC-I surface expression.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunodeficiency virus type 1 Negative Regulatory Factor – Src-family kinase Src homology 3 interface (Nef-SH3 interface).